Global IPS Cell-derived Platelets Market Growth (Status and Outlook) 2025-2031

The global IPS Cell-derived Platelets market size is predicted to grow from US$ 2.2 million in 2025 to US$ 3.1 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031.

iPS cell-derived platelets are platelets that are differentiated from induced pluripotent stem cells (iPS cells). iPS cells are a type of pluripotent stem cells that are reprogrammed into adult somatic cells (such as skin cells) with similar properties to embryonic stem cells by transfecting specific genes. iPS cells can differentiate into any cell type in the body, including blood cells. In this context, iPS cell-derived platelets refer to platelets that are produced by culturing precursor cells derived from iPS cells (such as platelet-producing megakaryocytes). These platelets can be cultured in vitro and used in the medical field to replace donor platelets, especially for the treatment of diseases caused by insufficient platelet count or abnormal function.

iPS cell-derived platelets, as an important breakthrough in the field of regenerative medicine, have received widespread attention in recent years. iPS cells (induced pluripotent stem cells) have extremely strong differentiation potential and can generate pluripotent stem cells similar to embryonic stem cells by reprogramming adult somatic cells. This technology not only provides new ideas for cell therapy and tissue repair, but also opens up new directions for the production of blood products. By deriving platelets from iPS cells, new treatment options can be provided for patients with diseases such as platelet deficiency and platelet dysfunction, and the problem of global shortage of blood products can also be alleviated.

At present, the research on iPS cell-derived platelets is still in its early stages, and many research institutions and biotechnology companies are committed to the development and optimization of this technology. Platelets, as a cell with special functions, are responsible for hemostasis and coagulation in the body, so the safety and effectiveness of their clinical application are crucial.

At present, the research on iPS cell-derived platelets is mainly concentrated in the laboratory and preclinical stages. Some research institutions and biopharmaceutical companies in Japan, the United States and Europe have made some progress in this field. However, the current production of iPS cell-derived platelets still faces some difficulties, including complex production processes, high costs, and the fact that the functions of platelets are still different from those of natural platelets.

Despite this, the prospects for the iPS cell-derived platelet market are still broad. The global blood products market has grown year by year, but the shortage of platelet supply has always been an issue that cannot be ignored. A large number of platelets are needed every year to meet clinical needs, especially in groups such as cancer patients, blood disease patients, and surgical patients. Traditional blood products rely on voluntary donors, but due to the limited number of donors, the supply of platelets is often in short supply. The emergence of iPS cell-derived platelets may break this limitation and provide a more stable and efficient alternative to meet market demand.

LPI (LP Information)' newest research report, the “IPS Cell-derived Platelets Industry Forecast” looks at past sales and reviews total world IPS Cell-derived Platelets sales in 2024, providing a comprehensive analysis by region and market sector of projected IPS Cell-derived Platelets sales for 2025 through 2031. With IPS Cell-derived Platelets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world IPS Cell-derived Platelets industry.

This Insight Report provides a comprehensive analysis of the global IPS Cell-derived Platelets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on IPS Cell-derived Platelets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global IPS Cell-derived Platelets market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for IPS Cell-derived Platelets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global IPS Cell-derived Platelets.

This report presents a comprehensive overview, market shares, and growth opportunities of IPS Cell-derived Platelets market by product type, application, key players and key regions and countries.

Segmentation by Type:
In Vivo Regeneration
In Vitro Regeneration

Segmentation by Application:
Cancer
Blood Disease
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Megakaryon Corporation
Renerval Therapeutics
Xueji Shengwu
Help Therapeutics
Cynata Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.